EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes

Niels B Dalsgaard, Lærke S Gasbjerg, Mads M Helsted, Laura S Hansen, Nina L Hansen, Kirsa Skov-Jeppesen, Bolette Hartmann, Jens J Holst, Tina Vilsbøll, Filip K Knop

Bone · 2023

DOI: 10.1016/j.bone.2023.116687 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Bone, 2023. Verfasst von Niels B Dalsgaard und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. Hauptthemen laut MEDLINE: Bone Resorption, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Københavns Universitet, A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal, Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: The alpha-glucosidase inhibitor acarbose is an antidiabetic drug delaying assimilation of carbohydrates and, thus, increasing the amount of carbohydrates in the distal parts of the intestines, which in turn increases circulating levels of the gut-derived incretin hormone glucagon-like peptide 1 (GLP-1). As GLP-1 may suppress bone resorption, acarbose has been proposed to potentiate meal-induced suppression of bone resorption. We investigated the effect of acarbose treatment on postprandial bone resorption in patients with type 2 diabetes and used the GLP-1 receptor antagonist exendin(9-39)NH2 to disclose contributory effect of acarbose-induced GLP-1 secretion. METHODS: In a randomised, placebo-controlled, double-blind, crossover study, 15 participants with metformin-treated type 2 diabetes (2 women/13 men, age 71 (57-85 years), BMI 29.7 (23.6-34.6 kg/m2), HbA1c 48 (40-74 mmol/mol)/6.5 (5.8-11.6 %) (median and range)) were subjected to two 14-day treatment periods with acarbose and placebo, respectively, separated by a six-week wash-out period. At the end of each period, circulating bone formation and resorption markers were assessed during two randomised 4-h liquid mixed meal tests (MMT) with infusions of exendin(9-39)NH2 and saline, respectively. Glucagon-like peptide 2 (GLP-2) was also assessed. RESULTS: Compared to placebo, acarbose impaired the MMT-induced suppression of CTX as assessed by baseline-subtracted area under curve (P = 0.0037) and nadir of CTX (P = 0.0128). During acarbose treatment, exendin(9-39)NH2 infusion lowered nadir of CTX compared to saline (P = 0.0344). Neither parathyroid hormone or the bone formation marker procollagen 1 intact N-terminal propeptide were affected by acarbose or GLP-1 receptor antagonism. Acarbose treatment induced a greater postprandial GLP-2 response than placebo treatment (P = 0.0479) and exendin(9-39)NH2 infusion exacerbated this (P = 0.0002). CONCLUSIONS: In patients with type 2 diabetes, treatment with acarbose reduced postprandial suppression of bone resorption. Acarbose-induced GLP-1 secretion may contribute to this phenomenon as the impairment was partially reversed by GLP-1 receptor antagonism. Also, acarbose-induced reductions in other factors reducing bone resorption, e.g. glucose-dependent insulinotropic polypeptide, may contribute.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone ResorptionDiabetes Mellitus, Type 2AgedFemaleHumansMaleAcarboseBlood GlucoseCross-Over StudiesGastric Inhibitory PolypeptideGlucagon-Like Peptide 1Glucagon-Like Peptide 2Glucagon-Like Peptide-1 ReceptorInsulinPeptide FragmentsMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

AcarboseAlpha-glucosidase inhibitorCTXCarboxy-terminal type I collagen crosslinksExendin(9-39)NH(2)GLP-1GLP-2Glucagon-like peptide 1Glucagon-like peptide 2Gut-bone axisP1NPProcollagen type 1 N-nerminal propeptideType 2 diabetes

Substanzen

AcarboseBlood GlucoseGastric Inhibitory PolypeptideGlucagon-Like Peptide 1Glucagon-Like Peptide 2Glucagon-Like Peptide-1 ReceptorInsulinPeptide Fragments

Autor:innen und Institutionen

  • Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, De…
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Scienc…
  • Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denm…
  • Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of…

Förderung

  • Københavns Universitet
  • A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal
  • Novo Nordisk Fonden

Zitieren

APA

Dalsgaard, N. B., Gasbjerg, L. S., Helsted, M. M., Hansen, L. S., Hansen, N. L., Skov-Jeppesen, K., Hartmann, B., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2023). Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes. Bone. https://doi.org/10.1016/j.bone.2023.116687

Vancouver

Dalsgaard NB, Gasbjerg LS, Helsted MM, Hansen LS, Hansen NL, Skov-Jeppesen K, et al. Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes. Bone. 2023. doi:10.1016/j.bone.2023.116687

BibTeX
@article{Dalsgaard2023,
  author = {Dalsgaard, Niels B and Gasbjerg, Lærke S and Helsted, Mads M and Hansen, Laura S and Hansen, Nina L and Skov-Jeppesen, Kirsa and Hartmann, Bolette and Holst, Jens J and Vilsbøll, Tina and Knop, Filip K},
  title = {Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes},
  journal = {Bone},
  year = {2023},
  doi = {10.1016/j.bone.2023.116687}
}
Kostenlos starten →